Unmatched cohort | Matched cohort | |||||
---|---|---|---|---|---|---|
TACE | SBRT | p value | TACE | SBRT | p value | |
All patients | n = 367 | n = 35 | n = 70 | n = 35 | ||
Target lesions | 367 | 46 | 70 | 46 | ||
Local tumor controlb n (%) [95%CI] | 273 (74.4) [70.0–79.0]a | 39 (84.8) [71.9–96.9] | 0.146 | 58 (82.9) [74.3–91.4] | 39 (84.8) [71.9–96.9] | 0.805 |
1-year-mortality n (%) [95%CI] | 141 (38.4) [33.8–43.6] | 17 (53.1) [37.5–71.9] | 0.073 | 37 (52.9) [40.0–64.3] | 17 (53.1) [37.5–68.8] | 0.989 |
BCLC B | n = 29 | n = 24 | n = 49 | n = 24 | ||
Target lesions | 299 | 23 | 49 | 23 | ||
Local tumor control n (%) [95%CI] | 225 (75.3) [70.6–80.2] | 19 (82.6) [66.7–95.8] | 0.612 | 41 (83.7) [72.3–93.5] | 19 (82.6) [66.7–95.8] | 0.847 |
1-year-mortality n (%) [95%CI] | 100 (33.4) [28.1–39.1] | 11 [45.8) [30.0–71.4] | 0.120 | 20 (40.8) [26.9–55.0] | 11 (45.8) [29.2–70.8] | 0.616 |
BCLC C | n = 68 | n = 11 | n = 21 | n = 11 | ||
Target lesions | 68 | 23 | 21 | 23 | ||
Local tumor control n (%) [95%CI] | 48 (70.6) [60.0–81.0] | 20 (87.0) [72.2–100] | 0.272 | 17 (81.0) [64.0–95.8] | 20 (87.0) [72.2–100] | 0.648 |
1-year-mortality n (%) [95%CI] | 41 (60.3) [48.3–70.9] | 6 (5.4) [27.3–90.0] | 0.999 | 17 (81.0) [64.0–95.8] | 6 (5.4) [27.3–90.0] | 0.397 |